Replies to post #3819 on Revance Therapeutics Inc (RVNC)

[radford]

As I said, I expect the CD approval to be based primarily on the strength of the clinical data package. While Revance has had some execution problems with manufacturing, IMO they have done a very thorough job of conducting the clinical trials. I don't recall any FDA issues with glabellar (sp?) lines clinical trials. There are others here who could better comment on the quality of the CD trial data but from my recollection of the results I would consider approval to be highly likely. Maybe that equates to a 90/10 probability of approval.

[jmkobers]

Next up, 25?

$RVNC Just reviewed the June 6th recording from William Blair. Overall, it feels the Daxxi launch not going that great and CEO was overall very cautious and tried to downplay near term expectations. Will not be surprised if this trends towards $25 in coming weeks.

— DeepValue (@ValueDig) June 10, 2023

Thanks for the hint. This is alarming and the share price reflects it. At most, I expect a run-up towards the PDUFA date in August but I don't want to own the ticker. As a long term invest a disaster. 0.6% performance in 5 years if you were always invested. I think it's a good… pic.twitter.com/CTliF65OTd

— Monaco (@monaco_biotech) June 10, 2023